Harren Jhoti

Harren Jhoti (born 1962)[1] FRS FMedSci FRSB FRSC is a structural biologist whose main interest has been rational drug design.[4] He is President & Chief Executive Officer (CEO) of Astex Pharmaceuticals in Cambridge, a biotechnology company he co-founded with Tom Blundell and Chris Abell in 1999.[5][4] He pioneered the development of fragment-based lead discovery, an approach now widely used in industry and academia to discover new medicines.[6][7]

Harren Jhoti

FRS FMedSci FRSB FRSC
Harren Jhoti at the Royal Society admissions day in London, July 2018
Born1962 (age 58–59)[1]
India
Alma mater
Known forAstex
AwardsChemistry World Entrepreneur of the Year (2007)[3]
Scientific career
FieldsDrug discovery
Structural biology
InstitutionsAstex
GlaxoWellcome
University of Oxford
ThesisX-ray structural studies on transferrins (1989)
InfluencesTom Blundell
David Ian Stuart[3]
Websiteastx.com/portfolio-item/harren-jhoti/

Astex's first drug, called Kisqali, which originated from a collaboration with Novartis, was approved in 2017 for patients with metastatic breast cancer in the United States and European Union.[4] In 2013 Astex was acquired by Otsuka Pharmaceutical for $886m, and operates as a wholly owned subsidiary of the Japanese company. Prior to Astex, Jhoti was Head of Structural Biology at GlaxoWellcome (now GSK).[4]

References
  1. Anon (2016). "Jhoti, Dr Harren". Who's Who. ukwhoswho.com (online Oxford University Press ed.). A & C Black, an imprint of Bloomsbury Publishing plc. doi:10.1093/ww/9780199540884.013.286522. (subscription or UK public library membership required) (subscription required)
  2. Jhoti, Harren (1989). X-ray structural studies on transferrins. London.ac.uk (PhD thesis). University of London. OCLC 940322045. Copac 29529053.
  3. Houlton, Sarah (2008). "Harren Jhoti profile" (PDF). Rsc.org. Chemistry World.
  4. Anon (2018). "Dr Harren Jhoti FRS". Royalsociety.org. London: Royal Society. Archived from the original on 2018-05-14. One or more of the preceding sentences incorporates text from the royalsociety.org website where:
    “All text published under the heading 'Biography' on Fellow profile pages is available under Creative Commons Attribution 4.0 International License.” --"Archived copy". Archived from the original on 2016-11-11. Retrieved 2018-05-23.CS1 maint: archived copy as title (link) CS1 maint: bot: original URL status unknown (link)
  5. "Harren Jhoti – Astex". Astx.com. Retrieved 23 May 2018.
  6. "Dr Harren Jhoti - The Academy of Medical Sciences". Acmedsci.ac.uk. Retrieved 23 May 2018.
  7. Jhoti, Harren; Williams, Glyn; Rees, David C.; Murray, Christopher W. (2013). "The 'rule of three' for fragment-based drug discovery: where are we now?". Nature Reviews Drug Discovery. 12 (8): 644–644. doi:10.1038/nrd3926-c1. ISSN 1474-1776. PMID 23845999.

 This article incorporates text available under the CC BY 4.0 license.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.